A 3-year-old boy in Texas had run out of standard options. His liver cancer had spread to his lungs and come back after chemotherapy and three surgeries. Then he got two infusions of an experimental immune cell therapy. Twelve months later, doctors can’t find any cancer in his body.
The case was published in The New England Journal of Medicine in September 2026. It’s one child, so I want to be careful about what it does and doesn’t prove. But it’s a big result for a field that has struggled for years to get immunotherapy working against solid tumors.
What Hepatoblastoma Is and Why This Case Was So Hard to Treat
Hepatoblastoma is the most common liver cancer in children. It’s still rare, and it usually shows up before age 3. Many kids do well with chemotherapy and surgery. Kids whose cancer spreads, comes back or stops responding to chemo have far fewer options.
This boy fit all three. When he was diagnosed, the tumor in his liver measured about 11 x 10 x 7 centimeters, which is huge for a toddler. It had already reached his lungs and possibly his bones. He went through three rounds of chemotherapy, surgery to remove the liver tumor, and two more operations to take out lung tumors. The cancer came back quickly anyway, with a new tumor in his lung.
How the GPC3-CAR T Cells Were Built to Hunt Liver Cancer
CAR T therapy takes a patient’s own T cells, which are immune cells that kill infected or abnormal cells, and re-engineers them in a lab. The modified cells get a new receptor that locks onto a specific marker on cancer cells. Then they go back into the patient’s bloodstream.
The approach works well against some blood cancers like leukemia and lymphoma. Solid tumors have been much harder. T cells tend to wear out before they finish the job, and tumors are good at shutting down immune attacks.
The team at Baylor College of Medicine and Texas Children’s Hospital made two key changes:
- A new target. The cells were built to recognize glypican-3 (GPC3), a protein found in large amounts on liver cancer cells and rarely on healthy adult tissue.
- Built-in boosters. The cells also carry genes for two immune signaling proteins, interleukin-15 and interleukin-21. In lab studies, these helped the T cells survive longer and kill tumor cells more effectively. Researchers call these “armored” CAR T cells.
This was part of the CARE study (NCT04715191), the first trial of this design in humans.
The Results: Partial Response, Then Complete Remission
After the first infusion, CT scans showed the tumors shrinking. His alpha-fetoprotein (AFP) level also dropped. AFP is a blood marker that tracks how active hepatoblastoma is.
Eight weeks later he got a second infusion. Follow-up scans showed no remaining cancer, only scar tissue where the tumors had been. He was still disease-free at the one-year mark.
The safety results matter just as much. CAR T therapy can trigger cytokine release syndrome, a dangerous immune overreaction that can land patients in intensive care. This child had no cytokine release syndrome and no dose-limiting side effects. The whole treatment was done on an outpatient basis.
“A durable complete response in a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting,” said first author Dr. David Steffin, a pediatric oncologist at Baylor.
Could This Therapy Help Adults With Liver Cancer, Too?
I’ll be direct here. This is a single patient in an early-phase trial. We don’t know yet how many children will respond this way, how long remissions will last, or what side effects show up in a larger group. Dr. Andras Heczey of Seattle Children’s, a co-author, called it “evidence that these novel CAR T cells may be a safe and effective modality for hepatoblastoma.” May is the key word.
Still, the implications go well beyond pediatric cancer. Liver cancer is the third leading cause of cancer death worldwide, and GPC3 shows up on adult liver tumors too. Seattle Children’s is already running a related trial called IMPACT (NCT07148050). If this design holds up, it could help adults with liver cancer as well as children.
The bigger lesson is that the immune system, given the right instructions and enough staying power, can clear cancer that surgery and chemo couldn’t.
My Personal RX on Keeping Your Immune System Ready to Fight
Most of us will never need engineered T cells. But your own immune cells are checking your body for abnormal cells every day, and how you live affects how well they do that job. This case is a good reminder that the immune system is one of the strongest cancer defenses you have.
Here’s what I tell my patients to do to keep it strong, and to protect their liver too:
- Make sleep a priority. Aim for 7 to 9 hours. Deep sleep is when your body produces and redistributes key immune cells, and chronic short sleep lowers natural killer cell activity.
- Feed your gut. About 70% of your immune tissue sits in your gut. Eat fiber-rich vegetables, beans and fermented foods. If you need extra help, a targeted probiotic like MindBiotic supports the gut microbiome that trains your immune cells.
- Protect your liver from alcohol. Heavy drinking is a leading cause of liver damage and liver cancer in adults. Keep it to no more than one drink a day for women and two for men, or skip it entirely.
- Get vaccinated against hepatitis B and screened for hepatitis C. Chronic viral hepatitis is a major driver of adult liver cancer. Both are preventable or treatable.
- Watch your waistline. Fatty liver disease is now one of the fastest-growing causes of liver cancer. Losing even 5 to 10% of your body weight can reduce liver fat in a meaningful way.
- Check your magnesium. Magnesium is involved in hundreds of enzyme reactions, including the ones that activate T cells. Leafy greens, nuts and seeds are great sources, and Magnesium Essentials can fill the gap if your diet falls short.
- Move every day. Regular moderate exercise improves immune surveillance and lowers inflammation. A brisk 30-minute walk counts.
- Reset your whole system at once. If you’re not sure where to start, the Gut Brain Reset Bundle combines the tools I use with patients to rebuild gut health, mood and energy together.
- Know your child’s warning signs. In young children, a swollen or firm belly, a lump in the abdomen, poor appetite or unexplained weight loss needs a prompt visit to the pediatrician. Catching it early changes outcomes.
- Ask about clinical trials. If you or someone you love has a hard-to-treat cancer, ask the oncology team whether a trial is an option. This boy’s outcome came from one. Searching ClinicalTrials.gov is a good first step, and my guide Optimizing Your Health & Wellbeing walks you through how to talk with your doctors.
Sources:
- Baylor College of Medicine. (2026). CARE study reports complete regression of liver cancer in a child treated with novel immunotherapy. https://www.bcm.edu/news/care-study-reports-complete-regression-of-liver-cancer-in-a-child-treated-with-novel-immunotherapy
- Dockrill, P. (2026, September 15). A 3-year-old’s metastatic cancer disappeared after two doses of experimental therapy. ScienceAlert. https://www.sciencealert.com/a-3-year-olds-metastatic-cancer-disappeared-after-two-doses-of-experimental-therapy
- Pharmacy Times. (2026, September 22). Armored CAR T-cell therapy produces durable complete response in pediatric solid tumors. https://www.pharmacytimes.com/view/armored-car-t-cell-therapy-produces-durable-complete-response-in-pediatric-solid-tumors
- Steffin, D., Courtney, A. N., Choe, M., et al. (2026). Complete regression of hepatoblastoma after interleukin-15- and interleukin-21-coexpressing CAR T-cell therapy. The New England Journal of Medicine, 395(10), 1029–1032. https://doi.org/10.1056/NEJMc2605958
- U.S. National Library of Medicine. (2021). Interleukin-15 and -21 armored glypican-3-specific chimeric antigen receptor expressing autologous T cells for the treatment of children with solid tumors (CARE) (Identifier NCT04715191). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04715191
